To address whether BRAF inhibition induces SOX2 expression in melanoma, we treated A375, SK-MEL-5, and A2058 cells, which express BRAFV600E, with PLX4032 (vemurafenib) and GSK2118436 (dabrafenib), two selective BRAFi (2, 16, 17). This evidence concerns the gene SOX2 and melanoma.